Comparative Efficacy of PD‐1 Inhibitor‐Based Neoadjuvant Chemoimmunotherapy Regimens for Resectable Stage II–IIIa NSCLC: A Real‐World Retrospective Study
ABSTRACT Background Although neoadjuvant chemoimmunotherapy has emerged as a promising approach for resectable non‐small cell lung cancer (NSCLC), comparative real‐world data on different PD‐1 inhibitors are limited. This study compared the clinical efficacy, pathological response, survival, and saf...
Saved in:
| Main Authors: | Bo Yan, Xiaoxuan Sun, Yan Sheng, Ran Zhang, Yanjun Su, Yulong Chen |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.70123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Is adjuvant immunotherapy necessary after neoadjuvant chemoimmunotherapy in patients with resectable stage III NSCLC? A two-center real-world study
by: Song Guan, et al.
Published: (2025-07-01) -
Four-year follow-up from the phase 2 study TD-NICE: neoadjuvant treatment of tislelizumab combined with chemotherapy in resectable esophageal squamous cell carcinoma
by: Yajie Mao, et al.
Published: (2025-08-01) -
MRI-based texture analysis for the evaluation of the response to neoadjuvant chemoimmunotherapy in locally advanced head and neck squamous cell carcinoma
by: Haoran Wei, et al.
Published: (2025-07-01) -
Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma
by: Jun-Peng Lin, et al.
Published: (2025-08-01) -
Pathological complete response and prognostic predictive factors of neoadjuvant chemoimmunotherapy in early stage triple-negative breast cancer
by: Xuwei Chen, et al.
Published: (2025-05-01)